本期科普详解全球首个III期成功的mRNA癌症疫苗,拆解其量身定制的研发逻辑、防复发原理,客观分析现存挑战与未来多癌种应用前景,带大家看懂癌症治疗的全新突破方向。
参考文献:
Merck & Moderna. INTerpath-001 Phase 3 Trial of intismeran autogene (V940/mRNA-4157) plus Keytruda met endpoints of RFS and DMFS. 2026-08-19. Merck公告
Weber JS, et al. KEYNOTE-942/mRNA-4157-P201 five-year follow-up. Journal of Clinical Oncology, 2026. DOI: 10.1200/JCO-26-00835
全球肿瘤快讯(北京大学肿瘤医院). 全球首个mRNA肿瘤疫苗Ⅲ期阳性数据公布. 2026-09-23. 链接
Russo M. Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'? Fierce Biotech, 2026-09-11.
Personalized Cancer Vaccines: What Challenges Remain? Medscape, 2026-09-28(含TG4050头颈癌数据).
Rojas LA, et al. BioNTech BNT122 personalized mRNA vaccine in pancreatic cancer. Nature, 2023/后续随访数据.

